Finally, in a PDX model of AML cells harboring MLL-AF9 and FLT3 mutation, co-treatment with ziftomenib and venetoclax or OTX015 yielded significantly greater reduction in AML burden and improvement in survival compared to each agent alone without significant host toxicity. The gene discussed is MLLT3; the disease is acute myeloid leukemia.